project id: TCGA-PRAD; case submitter id: TCGA-YL-A8SL; analyte type: DNA; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.86; concentration: 0.16; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.03; rna integrity number: 9.4; age at index: 74; days to birth: -27033; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1937; age at diagnosis: 27033; ajcc clinical m: M0; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 987.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to sample procurement: 0; initial weight: 760.0; portion submitter id: TCGA-YL-A8SL-01B-21; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 30.0; percent stromal cells: 20.0; percent tumor cells: 50.0; percent tumor nuclei: 60.0;